Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., ...

How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors

Tarsus Pharmaceuticals recently dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults ...
Targeted Oncology

Infection Risk Management and Prophylactic Strategies for Patients with R/R MM

Dr. Costa addresses the primary clinician concern regarding BCMA-directed T-cell engagers: infection risk. Early trials ...
The American Journal of Managed Care

Expanding ACCESS: Transplant Strategy Boosts Survival in Blood Cancers, Offers Potential Savings

A hematopoietic stem cell transplant (HSCT) can restore the body’s ability to produce healthy blood cells following chemotherapy or radiation, which wipes out diseased bone marrow. Armed with new ...